Skip to main content

Table 4 Effects of different MTNR1B rs10830963 genotypes in T2DM patients on clinical traits determined before and after nateglinide treatment

From: Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients

Parameters

CC(n = 26)

CG(n = 26) + GG(n = 8)

P value

N (male/female)

26 (16/10)

34(20/14)

0.902Δ

FPG (mmol/L)

 Before

10.73 ± 2.05

10.81 ± 1.92

0.877

 After

6.98 ± 1.35

7.94 ± 1.23

0.006*

 DV

− 3.75 ± 1.68

− 2.87 ± 1.32

0.027*

PPG (mmol/L)

 Before

14.51 ± 4.31

13.04 ± 4.72

0.220

 After

9.34 ± 3.24

9.27 ± 3.49

0.937

 DV

− 5.17 ± 4.08

− 3.77 ± 3.19

0.141#

FINS (mU/L)

 Before

8.82 ± 6.81

7.80 ± 4.20

0.478

 After

10.18 ± 6.60

9.32 ± 3.64

0.522

 DV

1.36 ± 4.10

1.84 ± 3.80

0.641

PINS (mU/L)

 Before

31.42 ± 20.47

27.47 ± 16.43

0.410

 After

48.41 ± 19.78

37.13 ± 20.87

0.038*

 DV

16.99 ± 17.82

9.66 ± 19.37

0.138

HOMA-IR

 Before

4.48 ± 2.88

3.24 ± 1.73

0.066

 After

3.39 ± 2.12

2.43 ± 1.18

0.072

 DV

− 0.89 ± 1.93

− 0.79 ± 1.31

0.704

HOMA-β

 Before

27.75 ± 16.03

24.08 ± 17.32

0.405

 After

68.62 ± 45.21

49.21 ± 24.36

0.037*

 DV

40.87 ± 23.52

25.13 ± 19.21

0.006*

HbA1c (%)

 Before

9.79 ± 1.86

9.15 ± 2.26

0.246#

 After

7.00 ± 0.84

7.01 ± 1.05

0.968

 DV

− 2.79 ± 1.53

− 2.14 ± 1.74

0.137

TG (mmol/L)

 Before

2.46 ± 1.96

2.31 ± 1.90

0.766

 After

2.21 ± 1.91

1.79 ± 1.23

0.306

 DV

− 0.25 ± 1.95

− 0.52 ± 1.58

0.096#

TC (mmol/L)

 Before

5.27 ± 1.69

5.22 ± 1.15

0.892#

 After

4.84 ± 1.12

4.89 ± 1.37

0.880#

 DV

− 0.43 ± 1.53

− 0.33 ± 1.09

0.769#

HDL-c (mmol/L)

 Before

1.42 ± 0.51

1.47 ± 0.47

0.695#

 After

1.35 ± 0.55

1.43 ± 0.51

0.563#

 DV

− 0.07 ± 0.68

− 0.04 ± 0.46

0.839

LDL-c (mmol/L)

 Before

3.28 ± 1.19

3.18 ± 1.05

0.731#

 After

3.19 ± 1.20

3.11 ± 1.07

0.786

 DV

− 0.09 ± 1.26

− 0.07 ± 1.08

0.948

  1. BMI body mass index, WHR waist to hip ratio, FPG fasting plasma glucose, PPG postprandial plasma glucose, FINS fasting serum insulin, PINS postprandial serum insulin, HOMA-IR homeostasis model assessment for insulin resistance, HOMA-β Homeostasis model assessment for islet β cell function, HbA1c hemoglobin A1c, TG triglyceride, TC total cholesterol, HDL-c high-density lipoprotein-cholesterol, LDL-c low-density lipoprotein-cholesterol, DV differential values (post-administration minus pre-administration)
  2. Data are given as (mean ± SD). ΔP values are determined by the Pearson chi-square test. #P values are determined by the Kruskal–Wallis test. *P < 0.05